TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03187691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Encochleated Amphotericin B (CAMB)
Description: Lipid-crystal nano-particle formulation amphotericin B
Study: NCT02112331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raw human milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized human milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pasteurized-homogenized human milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastric samples
Study: NCT01823692

Intervention type: OTHER
Group type: OTHER
Intervention: ultrasonography
Description: after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
Study: NCT03383120

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Laser treatment of the peri-implantitis lesion includes mechanical debridement of the implant using an ultrasonic device and plastic curettes followed by diode laser sub-mucosal application for 90 seconds. This is repeated two more times at one-week intervals.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment with adjunctive systemic antibiotics
Description: Mechanical debridement of the implant will be done in a similar manner to the test group (without laser application) followed by open flap debridement 2 weeks after, and post-operative prescription of Amoxicillin and Metronidazole systemic antibiotics 3 times per day for a period of 1 week
Study: NCT02323282

Intervention type: DRUG
Group type: OTHER
Intervention: ropivacaine
Study: NCT04004247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal generator (AirVO2)
Description: High Flow Nasal Oxygenation
Study: NCT03273556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%
Description: The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).~A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)
Description: The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .~A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect.
Study: NCT01874301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High quantity probiotic
Description: The intervention type is food product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low quantity probiotic
Description: The intervention type is food product

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00852540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retpamulin Ointment, 1%
Description: Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: Adult and adolescent (=\>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects \<5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
Study: NCT05102604

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Avocado
Description: Subjects will eat one avocado in addition to their usual diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Habitual diet
Description: Subjects will eat their usual diet
Study: NCT03620370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Description: In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should in Pre-hospital or emergency room as early as possible after diagnosed ischemic stroke and uninterrupted during other treatments including mechanical thrombolytic therapy and standard clinical treatment.
Study: NCT01503203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core training
Description: Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Virtual Training
Description: The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Training
Description: Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
Study: NCT01008020

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: tea catechin extracts
Description: Tea catechin extracts 540 mg/day, are consumed for 5 months.
Study: NCT03324269

Intervention type: DEVICE
Group type: OTHER
Intervention: NOL
Description: After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value \<10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 20 / decrement of 1 ng/ml of remifentanil Ce NOL gradient \< 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.~Upon the incision and 2 minutes after skin incision, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value \<10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured.~The formula derived from the calibration phase will be tested during a single tetanic stimulation at remifentanil Ce of 4 ng/ml during the validation phase.
Study: NCT03924050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORIPALIMAB INJECTION(JS001 )
Description: TORIPALIMAB INJECTION(JS001 ) or Placebo, 240mg/6ml/vial, Q3W,up to 2 years of treatment.
Study: NCT03711968

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative treatment protocol
Description: A combination of: postural exercise with visual spatial tasks, relaxation, balance exercise, motricity improvement and cognitive rehabilitation.
Study: NCT02147639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium Nitrate - double dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Increased exercise intensity
Study: NCT04197245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline injection therapy in post-acne atrophic scars
Description: saline injection contains 0.9% isotonic sodium chloride solution
Study: NCT01584375

Intervention type: OTHER
Group type: OTHER
Intervention: Flat midline head position
Description: Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.~--------------------------------------------------------------------------------

Intervention type: OTHER
Group type: OTHER
Intervention: Right flat lateral head position
Description: Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
Study: NCT00944853

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid zinc syrup
Description: Liquid zinc syrup containing 5 mg zinc as zinc sulfate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc tablet
Description: Dispersible zinc tablet containing 5 mg zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Liquid placebo supplement
Description: Liquid placebo supplement containing 0 mg zinc
Study: NCT03149562

Intervention type: DRUG
Intervention: plasma transfusions
Description: These critical ill neonates with plasma transfusions

Intervention type: DRUG
Intervention: non-plasma transfusions
Description: These critical ill neonates without plasma transfusions
Study: NCT01046396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene cream 0.1% and adapalene lotion 0.1%
Description: adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene lotion 0.1%
Description: adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
Study: NCT02435992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02638194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active smoking of Tobacco Hookah for 2 hours
Study: NCT03244085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Study: NCT02638194

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to tobacco hookah second hand smoke

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit a win bar
Description: Participants will visit a wine bar for food and/or drinks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visit a win bar
Description: Participants will visit a wine bar for food and/or drinks
Study: NCT03052270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Insertion of Arabin pessary for the prevention of preterm delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Pessary
Description: Insertion of Arabin pessary for the prevention of preterm delivery
Study: NCT03530215

Intervention type: DRUG
Intervention: Antineoplastic and Immunomodulating Agents
Description: Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L
Study: NCT03244085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL-007 tablet
Description: Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
Study: NCT03076333

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
Study: NCT03336567

Intervention type: OTHER
Intervention: Telephonic interview
Description: Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.

Intervention type: OTHER
Intervention: Telephonic interview
Description: Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.

Intervention type: OTHER
Intervention: Telephonic interview
Description: Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.

Intervention type: OTHER
Intervention: Telephonic interview
Description: Subjects with cancer and Oncologists will undergo a semi-structured one-to-one telephonic interview for up to 90 and 60 minutes respectively.
Study: NCT01893125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV2197944

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01738425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIC-1001; 125 mg oral tablets
Description: Single ascending doses (SAD) from 125 mg to 1000 mg;~Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GIC-1001 matching placebo
Description: Single ascending doses (SAD) \[equivalent to active arm, 125 mg to 1000 mg\]~Multiple ascending doses, TID over 7 successive days \[equivalent to the active arm, 125 mg to 500 mg\]
Study: NCT02844426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifid triple viable capsule and pectin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Study: NCT03879772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: intranasal administration
Study: NCT05344482

Intervention type: OTHER
Intervention: Secukinumab
Description: Included all the patients treated with secukinumab
Study: NCT02501798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Drug: Methylphenidate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study: NCT03085030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antioxidant Formula
Description: Antioxidant tablet will be taken by the patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taken by the patients
Study: NCT04847726

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast enhanced ultrasound
Description: contrast enhanced ultrasound with perfluorobutane and sulfur hexafluoride

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Dynamic CT
Description: Participants underwent dynamic CT for hepatic lesion

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver MRI
Description: Participants underwent liver MRI for hepatic lesion
Study: NCT01203280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: icing massage
Description: The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
Study: NCT04254302

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WECARE web platform
Description: The WECARE intervention allows families of children with motor difficulties to access rehabilitation therapists. The primary therapist will be an occupational therapist or a physiotherapist who will have one day a week to deliver the intervention. The therapist will act as case manager to connect families with community-based services available in their region and work, according to a transdisciplinary model, with an interdisciplinary team on a needs-based basis. Patient engagement with the therapists and in the WECARE intervention will be ensured by the collaborative coaching approach used by therapists to attain meaningful motor outcomes, as selected by the primary respondent.
Study: NCT04482686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Treatment days 1, 4, and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline Hcl
Description: 10 day treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: 10 Day treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Zinc
Description: 10 Day treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: 10 day treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: 10 day treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 10 day treatment
Study: NCT03879772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate nasal spray
Description: intranasal administration
Study: NCT04482686

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin C
Description: 10 day treatment
Study: NCT00434005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, ascorbate
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: N-acetylcysteine, ascorbate
Description: NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matched appearance to acetylcysteine and ascorbate intervention

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: matched appearance to acetylcysteine and ascorbate intervention
Study: NCT04020627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BiPAP Group
Description: BIPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/Positive Expiratory Pressure(PEP) device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP Group
Description: CPAP~- 1hr after every 6hrs for 3 days/week Conventional physiotherapy Treatment (Percussion, vibration, shaking) Modified postural drainage Incentive spirometer Blow bottle/Tissue blowing/PEP device
Study: NCT03266705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: bioequivalence study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: bioequivalence study
Study: NCT03051243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin and Basal Insulin
Description: Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basal Insulin and Bolus Insulin
Description: Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
Study: NCT00737373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 50mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600mg/m2 qd15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: 2600mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 qd15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85mg/m2 qd15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folinic acid
Description: 200mg/m2 qd15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 200mg/m2 qd15